SCHEMBL22553948

SCHEMBL22553948

O=C1CCCN1c1ccc(-c2cncc(-c3c[nH]c4ncccc34)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 3/20 0.45
GAA P10253 1/20 0.44
CDC7 O00311 5/20 0.43
PIM1 P11309 4/20 0.43
DBF4 Q9UBU7 1/20 0.43
CD38 P28907 1/20 0.42
DYRK1A Q13627 6/20 0.42
CAMKK1 Q8N5S9 1/20 0.41
CLK1 P49759 2/20 0.41
ROCK2 O75116 2/20 0.41
MAP4K4 O95819 2/20 0.41
PRKACA P17612 2/20 0.41
CDK2 P24941 2/20 0.41
GSK3B P49841 2/20 0.41
HIPK2 Q9H2X6 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
NTRK1 P04629 1/20 0.41
PIK3CA P42336 1/20 0.41
PRKAB2 O43741 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22553858 0.87 CD38 (0.45) PIM1CD38DYRK1ACLK1ROCK2
SCHEMBL30730850 0.87 CD38 (0.45) PIM1CD38DYRK1ACLK1ROCK2
SCHEMBL22553799 0.85 CD38 (0.42) CAMKK2CD38DYRK1ACLK1NTRK1
SCHEMBL22553811 0.85 JAK2 (0.46) CAMKK2CD38DYRK1ACLK1ROCK2
SCHEMBL22553899 0.85 NUDT1 (0.46) CD38DYRK1AROCK2MAP4K4PRKACA
SCHEMBL22553722 0.81 MAP4K1 (0.40) CAMKK2CD38DYRK1ACLK1CDK2
SCHEMBL22570987 0.81 DYRK1A (0.39) CAMKK2CD38DYRK1ACLK1CDK2
SCHEMBL22553851 0.80 ROCK2 (0.41) GAACD38ROCK2PRKAB2PRKAG1
SCHEMBL30730813 0.80 ROCK2 (0.41) GAACD38ROCK2PRKAB2PRKAG1
SCHEMBL22553754 0.80 BRD4 (0.49) GAAPIM1CD38CDK2HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US claimed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP claimed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US claimed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US disclosed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1A, PIP5K1B, PIP5K1C CAMKK2 488/4885GAA 1936/4885CDC7 681/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C CAMKK2 488/4885GAA 1936/4885CDC7 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.